Windtree Posts Mid-Stage Study Data On Lucinactant For COVID-19-Associated Respiratory Distress

Windtree Therapeutics Inc (NASDAQ:WINT) announced results from its Phase 2 study of lucinactant (KL4 surfactant) for severe COVID-19 associated acute respiratory distress syndrome (ARDS) and lung injury.

• The Phase 2 trial was designed to assess reconstituted lyophilized lucinactant's feasibility, safety, and tolerability. The study enrolled 20 critically ill patients who were intubated and on mechanical ventilation due to severe COVID-19 associated ARDS. 
• The trial demonstrated that intratracheal administration of reconstituted lyophilized lucinactant was generally safe and well-tolerated and could be safely administered to critically ill, mechanically ventilated COVID-19 patients.
• Related: Windtree Therapeutics Concludes Enrollment In Mid-Stage Cardiogenic Shock Study, Data Expected In April.
• Compared to earlier trials in non-COVID-19 ARDS where patients were administered Surfaxin, a different formulation of lucinactant, reconstituted lyophilized lucinactant was easier and faster to administer was associated with fewer peri-dosing side effects. 
• Price Action: WINT shares are down 6.59% at $1.02 during the market session on the last check Tuesday.